MedTrace Logo

Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

NCT02323737 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-12-30

No results posted yet for this study

Summary

Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Irinotecan and cisplatin

DRUG

Etoposide and cisplatin

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • yuankai shi, PhD · Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

  • xingsheng Hu · Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-06-30
Completion
2012-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323737 on ClinicalTrials.gov